Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 103,700 shares ...

The deal envisages 70 percent going to the French private equity company PAI and the remaining 30 percent remaining with the German company Fresenius. The sale price has not yet been disclosed ...

German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its ...

Fresenius plant, die Sparte Vamed durch Verkauf oder Liquidation von Unternehmensteilen zu schließen und andere Teile in bestehende Geschäftsbereiche zu integrieren.

Fresenius SE is planning to eliminate its Vamed unit by selling or winding down parts of the business and integrating other pieces into existing divisions, according to people familiar with the ...

Fresenius SE & Co. KGaA / Key word (s): Change in Forecast Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 07-May-2024 / 21:19 CET/CEST Disclosure of an inside information acc.

PAI to carve-out Vamed’s European rehabilitation biz for €853m EV The unit provides inpatient and outpatient rehabilitation services as well as specialist acute care.

Through its Helios and Vamed segments, Fresenius provides services related to healthcare facility operation, management, and construction. In its Helios segment, it aims to provide top-quality ...

Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, ...

Narrow-moat Fresenius SE FRE turned in decent second-quarter results and largely maintained its 2023 guidance, as external pressures are easing. Our EUR 52 fair value estimate has not changed ...

Fresenius said 332 million euros worth of writedowns on assets and provisions for expected financial burdens at Vamed resulted in a 20 million euro operating loss at the business.

EBIT before special items decreased by 5% or down 4% in constant currency to 956 million euros, mainly driven by the negative earnings performance at Fresenius Vamed.